Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer's, and Parkinson's disease, announces that it will present at Biotech Showcase 2025, an event expected to include over 3,200 healthcare professionals with more than 1,200 investors. The event will be held at the Hilton Hotel in Union Square, San Francisco during the J.P. Morgan Healthcare Week, and KLTO's Founder, CEO and Chairman, Dr. Joseph Sinkule, will give a presentation at 3:00 p.m. PT on Tuesday, January 14.
Biotech Showcase 2025 Presentation Details:
Date: Tuesday, January 14, 2025
Time: 3:00 PM PT
Track: Yosemite-C
Webcast Link: HERE
Webcast Archive: HERE
Commenting on being selected to speak at the conference, Dr. Sinkule stated: "I am delighted to have the honor of presenting at this prestigious conference. I welcome the opportunity of sharing novel information about our company and the secreted form of the Klotho anti-aging gene, 's-KL', the patent protected development platform on which our product candidates are being developed for ALS, Alzheimer's, and Parkinson's disease."
Dr. Sinkule continued: "It is apparent that, while there is a plethora of scientific literature about Klotho, it is still relatively unknown among many members of the global scientific community. At Klotho Neurosciences, we plan to expand the awareness of this intriguing 'master gene‘ and the role it may play in treating these devastating neurodegenerative diseases. In particular, we are working diligently towards entry into the clinic with ALS, and are actively seeking development partnerships with regard to Alzheimer's and Parkinson's, as well as a number of other age-related disorders."
Klotho Neurosciences has secured an exclusive worldwide license from Universitat Autònoma de Barcelona (UAB) and Institució Catalana de Recerca i Estudis Avançats (ICREA) in Spain. As a result, Klotho Neurosciences has the exclusive use of patents issued in the USA, Europe, and China for its innovative therapeutic approach. The patents cover a secreted splice variant of mammalian Klotho, s-KL. as a treatment for cognitive and behavioral impairments.
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ:KLTO), is a biopharmaceutical company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene and its novel delivery system (s-KL/AAV.myo) to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostics. Other assets include clinical-stage programs involving antibody biologics targeting cancer and autoimmune diseases, and drug delivery via a needle-free dry powder jet autoinjector called Nanoject. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
For more information, contact:
Eric Boyd
Investor Relations
Email: [email protected]
Website: www.klothoneuro.com
Forward-Looking Statements:
This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's research and development plans, the potential efficacy and safety of the Company's investigational therapies, anticipated timelines for preclinical studies and clinical trials, regulatory pathways, market opportunities, and the Company's ability to advance its programs and achieve its strategic objectives. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, but not limited to, uncertainties inherent in preclinical research, the initiation, timing, and results of clinical trials, the Company's ability to secure regulatory approvals, and the Company's ability to secure financing to support its development programs. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC's website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
